Clinical Trial Update: Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis [Phase 2]

View source ↗

Summary

Phase 2 dose schedule study of Elranatamab for newly diagnosed AL amyloidosis; trial is not yet Recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis Light-chain

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Amyloid Light-chain Amyloidosis | Phase 2 | Status: NOT_YET_RECRUITING